| RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). | |
| | |
MedLine Citation:
|
PMID: 19769599 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The low rate of response to antidepressants in treatment resistant depression (TRD) justifies studies of next-step therapies following a treatment failure. In TRD clinical trials, it is important to verify the accurate diagnosis of treatment resistance for all enrolled subjects using a reliable and valid instrument. Self-rated scales can reduce the impact of investigator bias and reduce the time burden for clinical researchers. The Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ) is a self-rated scale used to determine treatment resistance in major depressive disorder (MDD). The ADAPT-A study is a multi-center double-blind, placebo-controlled study of low-dose aripiprazole adjunctive to ADT among outpatients with TRD. At the screening assessment, potential subjects completed the MGH ATRQ. The ADAPT-A medical monitors subsequently performed remote patient interviews and obtained detailed medication histories. The data obtained from the MGH ATRQ and by the medical monitors were compared for congruency. Of the 186 patients enrolled by the local sites, no subjects deemed treatment resistant by the MGH ATRQ were found to be nonresistant by the medical monitors. In 76.3% (n = 142) of the subjects, the number of failed adequate antidepressant trials reported by the MGH ATRQ was concordant with the data collected by medical monitors. In 16.1% (n = 30) of all cases, the medical monitors found a greater number of failed trials; in 7.5% (n = 14) of cases, the medical monitors found fewer failed medication trials. The discrepancy was by more than one medication trial in only 4.0% (n = 7) of cases. We found the MGH ATRQ to be relatively concordant in its assessment of treatment resistance in depression compared with independent clinical researchers. Although the MGH ATRQ tended to underreport the number of unsuccessful treatment trials relative to the clinical interviews, its accuracy in cases it detected was confirmed by raters. |
| | |
Authors:
|
Gregory M Chandler; Dan V Iosifescu; Mark H Pollack; Steven D Targum; Maurizio Fava |
Related Documents
:
|
16524669 - Topical botulinum toxin to treat hyperhidrosis? no sweat! 10749449 - Fibrous osteodystrophy in dromedary camels (camelus dromedarius). 18928349 - Multimodal treatment for childhood attention-deficit/hyperactivity disorder. 15527679 - Medical therapy for ulcerative colitis: the state of the art and beyond. 8852729 - Developmental isolation and subsequent adult behavior of drosophila paulistorum. iii. a... 12915619 - Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, an... 10166539 - Some thoughts on becoming an acpe fellow (american college of physician executives). 16432599 - The persian version of the cardiff acne disability index. reliability and validity study. 887979 - Fatal poisoning with propoxyphene: report from 100 consecutive cases. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: CNS neuroscience & therapeutics Volume: 16 ISSN: 1755-5949 ISO Abbreviation: CNS Neurosci Ther Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-11-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101473265 Medline TA: CNS Neurosci Ther Country: England |
Other Details:
|
Languages: eng Pagination: 322-5 Citation Subset: IM |
Copyright Information:
|
© 2009 Blackwell Publishing Ltd. |
Affiliation:
|
Massachusetts General Hospital Clinical Trials Network and Institute, Boston, USA. chandlergreg@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neuroendocrine-Related Adverse Events Associated with Antidepressant Treatment in Children and Adole...
Next Document: Extracellular adherence protein (Eap) from S. aureus does not function as a superantigen.